RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – June 28, 2017) – Fennec Pharmaceuticals Inc. (TSX:FRX)(OTCQB:FENCF) today announced that the nominees listed in the management proxy circular dated May 19, 2017 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 27, 2017. Detailed results of the vote for the election of directors are set out below:
| Name of Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld | ||||
| Dr. Khalid Islam | 9,243,659 | 99.97% | 2,562 | 0.03% | ||||
| Mr. Adrian Haigh | 9,243,660 | 99.97% | 2,561 | 0.03% | ||||
| Mr. Chris A. Rallis | 9,243,017 | 99.97% | 3,204 | 0.03% | ||||
| Mr. Marco Brughera | 9,243,813 | 99.97% | 2,408 | 0.03% | ||||
| Mr. Rostislav Raykov | 9,243,761 | 99.97% | 2,460 | 0.03% | ||||
Shareholders voted 97.33% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 99.98% in favour of approving the Company’s Shareholder Rights Plan, and 99.96% in favour of the compensation paid to the Company’s named executive officers.
Rosty Raykov
Chief Executive Officer
(919) 636-5144